SI1883397T1 - Disperzibilne tablete bosertana - Google Patents

Disperzibilne tablete bosertana

Info

Publication number: SI1883397T1
Authority: SI; Slovenia
Prior art keywords: dispersible; bosertan; tablet; pyrimidin; benzenesulfonamide
Prior art date: 2005-05-17

Application number

SI200630581T

Other languages

English (en)

Inventor

Lovelace Holman

Timm Trenktrog

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-17

Filing date

2006-05-15

Publication date

2010-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1883397(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-05-15 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2010-04-30 Publication of SI1883397T1 publication Critical patent/SI1883397T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SI200630581T 2005-05-17 2006-05-15 Disperzibilne tablete bosertana SI1883397T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2005005367		2005-05-17
EP06744942A EP1883397B1 (en)	2005-05-17	2006-05-15	Dispersible bosertan tablet

Publications (1)

Publication Number	Publication Date
SI1883397T1 true SI1883397T1 (sl)	2010-04-30

Family

ID=37431647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200630581T SI1883397T1 (sl)	2005-05-17	2006-05-15	Disperzibilne tablete bosertana

Country Status (23)

Country	Link
US (3)	US7959945B2 (sl)
EP (1)	EP1883397B1 (sl)
JP (1)	JP4219399B2 (sl)
KR (2)	KR20080014002A (sl)
CN (1)	CN101175484B (sl)
AT (1)	ATE451914T1 (sl)
AU (1)	AU2006248593B2 (sl)
BR (1)	BRPI0610187B8 (sl)
CA (1)	CA2607098C (sl)
CY (1)	CY1110610T1 (sl)
DE (1)	DE602006011150D1 (sl)
DK (1)	DK1883397T3 (sl)
ES (1)	ES2336943T3 (sl)
IL (1)	IL187383A (sl)
MX (1)	MX2007014454A (sl)
NO (1)	NO339781B1 (sl)
NZ (1)	NZ564167A (sl)
PL (1)	PL1883397T3 (sl)
PT (1)	PT1883397E (sl)
RU (2)	RU2404774C2 (sl)
SI (1)	SI1883397T1 (sl)
WO (1)	WO2006123285A2 (sl)
ZA (1)	ZA200710903B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7959945B2 (en) *	2005-05-17	2011-06-14	Actelion Pharmaceuticals Ltd.	Dispersible bosentan tablet
US8664390B2 (en)	2007-06-29	2014-03-04	Generics (Uk) Limited	Process for the introduction of hydroxyethoxy side chain in bosentan
NZ587793A (en)	2008-02-08	2012-06-29	Generics Uk Ltd	Process for preparing bosentan
CN102272108A (zh)	2008-11-03	2011-12-07	基因里克斯(英国)有限公司	用于分析波生坦及相关物质的hplc方法以及这些物质作为参比标准和标记的用途
JP5850576B2 (ja) *	2010-07-06	2016-02-03	富士化学工業株式会社	ボセンタン固体分散体
CN102114005B (zh) *	2010-12-06	2012-12-12	武汉武药科技有限公司	一种波生坦胶囊及其制备方法
EP2696857A1 (en)	2011-04-11	2014-02-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical composition comprising bosentan
US9945862B2 (en)	2011-06-03	2018-04-17	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN104487057A (zh)	2012-05-11	2015-04-01	韩诺生物制药株式会社	波生坦控释口服制剂
KR101451327B1 (ko) *	2013-01-08	2014-11-03	안국약품 주식회사	보센탄의 제어방출성 다층 정제 및 그 제조방법
RU2559424C1 (ru) *	2014-06-18	2015-08-10	Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России)	Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
CN106660964B (zh)	2014-08-28	2021-09-03	卫材R&D管理有限公司	高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) *	2015-02-25	2024-04-02	Eisai R&D Management Co., Ltd.	Sposób tłumienia goryczy pochodnej chinoliny
CN104840965B (zh) *	2015-05-05	2018-05-08	重庆华邦制药有限公司	波生坦的制剂及其稳定剂
KR20160141045A (ko)	2015-05-27	2016-12-08	한올바이오파마주식회사	보센탄을 함유한 약학적 조성물
ES2886107T3 (es)	2015-06-16	2021-12-16	Prism Biolab Co Ltd	Antineoplásico
AU2016309356B2 (en)	2015-08-20	2021-06-24	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
MX380144B (es)	2017-02-08	2025-03-12	Eisai R&D Man Co Ltd	Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en)	2017-05-16	2018-11-22	Eisai R&D Management Co., Ltd.	Treatment of hepatocellular carcinoma
CN108703956A (zh) *	2018-08-21	2018-10-26	天津双硕医药科技有限公司	一种含有波生坦的固体药物组合物
EP4076398A4 (en)	2019-12-16	2024-01-03	Tenax Therapeutics, Inc.	LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
WO2023107066A2 (en) *	2021-12-07	2023-06-15	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Bosentan pharmaceutical compositions
WO2023128902A1 (en) *	2021-12-30	2023-07-06	Pharmactive Ilac Sanayi Ve Ticaret A.S.	Pharmaceutical compositions comprising bosentan and relevant excipients
EP4456897A4 (en)	2021-12-31	2025-12-10	Tenax Therapeutics Inc	ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
CN114533738A (zh) *	2022-02-19	2022-05-27	苏州海景医药科技有限公司	一种波生坦固体药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2086544C1 (ru) *	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
ES2082723B1 (es) *	1994-07-20	1996-10-01	Lilly Sa	Formulacion farmaceutica de fluoxetina en forma dispersable.
CA2355411A1 (en) *	2000-08-18	2002-02-18	Queen's University At Kingston	Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
AR040233A1 (es) *	2002-05-31	2005-03-23	Schering Corp	Polimorfos inhibidores de xantina fosfodiesterasa v
US20040102361A1 (en) *	2002-11-27	2004-05-27	Frederic Bodin	Pharmaceutical composition for the treatment of pulmonary arterial hypertension
KR100604034B1 (ko)	2003-10-08	2006-07-24	주식회사유한양행	암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
US7959945B2 (en) *	2005-05-17	2011-06-14	Actelion Pharmaceuticals Ltd.	Dispersible bosentan tablet

2006
- 2006-05-15 US US11/914,652 patent/US7959945B2/en active Active
- 2006-05-15 AU AU2006248593A patent/AU2006248593B2/en active Active
- 2006-05-15 SI SI200630581T patent/SI1883397T1/sl unknown
- 2006-05-15 CA CA2607098A patent/CA2607098C/en not_active Expired - Fee Related
- 2006-05-15 EP EP06744942A patent/EP1883397B1/en active Active
- 2006-05-15 KR KR1020077028463A patent/KR20080014002A/ko not_active Ceased
- 2006-05-15 RU RU2007146395/15A patent/RU2404774C2/ru active
- 2006-05-15 PL PL06744942T patent/PL1883397T3/pl unknown
- 2006-05-15 MX MX2007014454A patent/MX2007014454A/es active IP Right Grant
- 2006-05-15 AT AT06744942T patent/ATE451914T1/de active
- 2006-05-15 JP JP2008510716A patent/JP4219399B2/ja active Active
- 2006-05-15 ES ES06744942T patent/ES2336943T3/es active Active
- 2006-05-15 BR BRPI0610187A patent/BRPI0610187B8/pt active IP Right Grant
- 2006-05-15 WO PCT/IB2006/051519 patent/WO2006123285A2/en not_active Ceased
- 2006-05-15 DK DK06744942.1T patent/DK1883397T3/da active
- 2006-05-15 KR KR1020107014762A patent/KR20100093105A/ko not_active Ceased
- 2006-05-15 DE DE602006011150T patent/DE602006011150D1/de active Active
- 2006-05-15 CN CN2006800166119A patent/CN101175484B/zh active Active
- 2006-05-15 NZ NZ564167A patent/NZ564167A/en unknown
- 2006-05-15 PT PT06744942T patent/PT1883397E/pt unknown
2007
- 2007-11-15 IL IL187383A patent/IL187383A/en active IP Right Grant
- 2007-12-10 NO NO20076325A patent/NO339781B1/no unknown
- 2007-12-14 ZA ZA200710903A patent/ZA200710903B/xx unknown
2010
- 2010-03-09 CY CY20101100220T patent/CY1110610T1/el unknown
- 2010-07-16 RU RU2010129460/15A patent/RU2010129460A/ru not_active Application Discontinuation
2011
- 2011-06-07 US US13/154,588 patent/US8309126B2/en active Active
2012
- 2012-09-27 US US13/628,780 patent/US20130023547A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7959945B2 (en)	2011-06-14
KR20100093105A (ko)	2010-08-24
RU2404774C2 (ru)	2010-11-27
HK1120212A1 (en)	2009-03-27
NZ564167A (en)	2009-12-24
DK1883397T3 (da)	2010-04-06
BRPI0610187B1 (pt)	2020-03-03
PT1883397E (pt)	2010-02-23
AU2006248593B2 (en)	2011-03-17
AU2006248593A1 (en)	2006-11-23
NO339781B1 (no)	2017-01-30
US20130023547A1 (en)	2013-01-24
EP1883397A2 (en)	2008-02-06
US8309126B2 (en)	2012-11-13
IL187383A (en)	2011-09-27
JP4219399B2 (ja)	2009-02-04
ES2336943T3 (es)	2010-04-19
DE602006011150D1 (de)	2010-01-28
KR20080014002A (ko)	2008-02-13
BRPI0610187B8 (pt)	2021-05-25
ATE451914T1 (de)	2010-01-15
US20110245281A1 (en)	2011-10-06
CN101175484B (zh)	2012-02-01
WO2006123285A2 (en)	2006-11-23
US20080193528A1 (en)	2008-08-14
CA2607098A1 (en)	2006-11-23
PL1883397T3 (pl)	2010-05-31
NO20076325L (no)	2008-02-04
CY1110610T1 (el)	2015-04-29
BRPI0610187A2 (pt)	2010-06-01
CA2607098C (en)	2012-04-10
MX2007014454A (es)	2008-02-07
EP1883397B1 (en)	2009-12-16
JP2008540512A (ja)	2008-11-20
IL187383A0 (en)	2008-02-09
RU2007146395A (ru)	2009-06-27
CN101175484A (zh)	2008-05-07
WO2006123285A3 (en)	2007-07-05
RU2010129460A (ru)	2012-01-27
ZA200710903B (en)	2008-12-31

Publication	Publication Date	Title
IL187383A0 (en)	2008-02-09	Dispersible bosertan tablet
IL193725A0 (en)	2009-05-04	Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
UY29500A1 (es)	2006-11-30	Proceso quimico
WO2007027238A3 (en)	2007-09-13	Jak kinase inhibitors and their uses
AU2018260844A1 (en)	2018-11-22	Processes of making and crystalline forms of a MDM2 inhibitor
WO2008144223A3 (en)	2009-02-05	Triazolyl aminopyrimidine compounds
MX2008012576A (es)	2008-10-10	Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
NO2014029I2 (no)	2014-11-18	Sofosbuvir. (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropyrimidin-1(2H)-yl)-4-fluor-3-hydroksy-4-metyltetrahydrofuran-2-yl)metoksy)-(fenoksy)fosforylamino)propanoat
MX2009005363A (es)	2009-06-05	Pirimidinas y su uso como antagonistas del receptor cxcr2.
IL181056A0 (en)	2007-07-04	Hiv inhibiting 5-substituted pyrimidines
ATE500232T1 (de)	2011-03-15	Kristalline form von 2-chlor-5-ä3,6-dihydro-3- methyl-2,6-dioxo-4-(trifluormethyl)-1-(2h)- pyrimidinylü-4-fluor-n-äämethyl-(1- methylethyl)aminoüsulfonylübenzamid
MX2010004576A (es)	2010-05-17	Derivados de pirimidina novedosos.
DE602004032321D1 (de)	2011-06-01	Die hiv-replikation inhibierende indan-substituierte pyrimidine
GEP20125410B (en)	2012-02-27	Solid preparation comprising alogliptin and pioglitazone
IL180760A0 (en)	2007-06-03	Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
CL2011003022A1 (es)	2012-07-13	Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
NZ705225A (en)	2016-11-25	Process for preparing antiviral compounds
TN2010000070A1 (en)	2011-09-26	Fused bicyclic pyrimidines
MX2010003326A (es)	2010-04-09	Formas solidas de (s)-etil 2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro -2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)-pirimidi n-4-il)fenil)propanoato y metodos de su uso.
ZA201002214B (en)	2011-06-29	3-methyl-2-((2s)-2-(4-(3-methyl-l,2,4-0xadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor
PH12021553264A1 (en)	2022-08-31	Pyrazolone and pyrimidine compound, and preparation method and use therefor
ATE420646T1 (de)	2009-01-15	Aminopyrimidine als kinase-modulatoren
TR201903012T4 (tr)	2019-03-21	Bosentan monohidratın ve bunun ara ürünlerinin hazırlanması için proses.
MX2011005611A (es)	2011-09-15	Sintesis y formas de sales novedosas de (r)-5-((e)-2-(pirrolidin-3 -il-vinil)pirimidina.
AP2157A (en)	2010-09-13	2-substituted pyrimidines.